Zist Fanavari Novin Biotechnology Institute | Iran
Dr. Mansoureh Azadeh Jouneghani is a seasoned molecular and cellular biologist, currently CEO of PreventiGene — a startup she launched in 2023 to promote cancer prevention through advanced genetic testing. With a Ph.D. in Cellular and Molecular Biology, she also founded and leads Zist Fanavari Novin Biotechnology Institute since 2011, and has taught at the university level for 20 semesters at Azad University. Over her career she has led and managed substantial research initiatives in cancer genomics, drug-resistance mechanisms in cancer (especially breast cancer), genomic biomarkers for multiple sclerosis and cardiovascular disease, athlete genomics for performance and injury prevention, and personalized medicine. She is proficient in gene expression analysis, RNA sequencing, CRISPR, bioinformatics, and high-throughput data analytics, and has supervised training in numerous molecular-biology lab techniques (PCR, qRT-PCR, ELISA, cell culture, Western blot). Her research output includes over 100 publications, covering peer-reviewed articles, conference papers, and laboratory-technique handbooks; her work has contributed significantly to genomic medicine and translational biotechnology. As a leader and educator she bridges academia, industry, and clinical research — advancing personalized medicine, improving genomic diagnostics, and fostering vocational biotech education. Her dedication continues to contribute to better health outcomes, scientific innovation, and capacity-building in biotechnology.
Featured Publications
Azadeh, M., Salehzadeh, A., Ghaedi, K., & Talesh Sasani, S. (2022). NEAT1 can be a diagnostic biomarker in breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: Integrated RNA targetome… Genes and Environment.
Fattahi Dolatabadi, N., Dehghani, A., Shahand, E., Yazdanshenas, M., et al. (2020). The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer.
Adami, B., Tabatabaeian, H., Ghaedi, K., Talebi, A., Azadeh, M., & Dehdashtian, E. (2019). miR-146a is deregulated in gastric cancer. Journal of Cancer Research and Therapeutics.
Assad Samani, L., Javadirad, S. M., Parsafar, S., Tabatabaeian, H., Ghaedi, K., et al. (2019). TP53 rs1625895 is related to breast cancer incidence and early death in Iranian population. Indian Journal of Clinical Biochemistry.
Dehghan, Z., Sadeghi, S., Tabatabaeian, H., Ghaedi, K., Azadeh, M., Fazilati, M., et al. (2017). *ESR1 single nucleotide polymorphism rs1062577 (c.3804T>A) alters the susceptibility of breast cancer risk in Iranian population. Gene.